|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
12 December 2020 |
|
Main ID: |
NCT01663935 |
|
Date of registration:
|
09/08/2012 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Vision Response to Dopamine Replacement
|
|
Scientific title:
|
Interventional Study of Levodopa Replacement on Retinal Function in Oculocutaneous Albinism |
|
Date of first enrolment:
|
October 17, 2012 |
|
Target sample size:
|
20 |
|
Recruitment status: |
Terminated |
|
URL:
|
https://clinicaltrials.gov/show/NCT01663935 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
|
|
Phase:
|
Phase 2
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Michael C Struck, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
University of Wisconsin, Madison |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- clinical diagnosis of oculocutaneous albinism
- age over 3 and weight over 25 lbs.
Exclusion Criteria:
- ocular only albinism
- ocular pathology other than albinism
- neurologic disease, history of myocardial infarction, history of clinical depression,
pregnancy
Age minimum:
3 Years
Age maximum:
N/A
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Oculocutaneous Albinism
|
|
Albinism
|
|
Intervention(s)
|
|
Drug: Levodopa/carbidopa
|
|
Primary Outcome(s)
|
|
Visual Acuity Change
[Time Frame: 3 months]
|
|
Secondary ID(s)
|
|
2012-0023
|
|
2016-1576
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|